Company profile

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Privately held: no public share price (Operating/licensing subsidiary of CSPC Pharmaceutical Group; no separate stock listing. Parent: CSPC Pharmaceutical Group Limited (HKEX 1093). [resolved 2026-08-05 by resolve-null-is-public; source: https://www.businesswire.com/news/home/20241212043058/en/BeiGene-Announces-Global-Licensing-Agreement-for-MAT2A-Inhibitor]) · China

Assets

(4 total)

4Total Assets

0Approved

4Phase 3 / Filed

0Phase 1–2 / Early

3Diseases

Showing 4 of 4 assets

		Target & Modality
Enlonstobart	Phase 3	PD-1Monoclonal antibody	Non-Small Cell Lung Cancer
HB1801	Phase 3	TubulinSmall molecule	Non-Small Cell Lung Cancer
Sirolimus for Injection (Albumin-bound)	Phase 3	mTOR (mechanistic target of rapamycin complex 1), via FKBP-12Small molecule	HR+/HER2- Breast Cancer HR+/HER2- Metastatic Breast Cancer
stapokibart	Phase 3	IL-4R-alphaMonoclonal antibody	Atopic Dermatitis

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.